Date: 13th July, 2026
Regulatory Disclosure Details
Nature of Disclosure: USFDA Warning Letter to Clinical Investigator associated with company's Bioequivalence Facility
Authority: United States Food and Drug Administration (USFDA)
Warning Letter Date: 10th July 2026
Date Company Became Aware: 12th July 2026
Inspection Period: 3rd March 2025 to 7th March 2025
Facility Affected: Company's Bioequivalence Facility at Vadodara
Nature of Observations: Pertains to observation regarding Informed Consent Form (ICF) in relation to a bioequivalence study. The observations do not relate to data integrity.
Impact Assessment: Based on Company's preliminary assessment, no material financial impact has been identified at this stage. The Warning Letter does not impose any restriction on the operations of the Company's Bioequivalence Facility.
Company Response: The Company is coordinating with the Clinical Investigator for submission of an appropriate response to the USFDA within the stipulated timeline.
Regulatory Reference: Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
No material disclosures under the following sections:
- KMP / Board / Auditor Changes
- Dividend Declaration or Non-Declaration
- Board Meeting Outcomes
- Financial Results
- Auditor's Report
- Disinvestment / Strategic Actions
- Media Release / Investor Communication